Results 41 to 50 of about 6,882 (175)

Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease

Scientific Reports, 2021
To assess the efficacy and safety of eltrombopag in connective tissue disease (CTD)-immune thrombocytopenia (ITP), we conducted this single-center retrospective observational study, including patients with refractory CTD-ITP who were treated with ...
Juan Wang, Min Dai, Qiong Fu, Sheng Chen
doaj   +1 more source

Intermittent versus Daily Eltrombopag Dosage Protocols for the Treatment of Primary Immune Thrombocytopenia: Real-Life Experience

Journal of Blood Medicine, 2020
Tamer A Elbedewy,1 Mohamed A Elsebaey,1 Reem A Elkholy,2 Dina M Tahoon,2 Samah A Elshweikh1 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Medical Pharmacology Department, Faculty of Medicine, Tanta University, Tanta,
Elbedewy TA, Elsebaey MA, Elkholy RA, Tahoon DM, Elshweikh SA   +4 more
doaj  

Evaluation of safety, efficacy and pharmacokinetics of Eltrombopag in patients with chronic immune thrombocytopenia: Meta-analysis of randomized controlled trials Authors

Research Results in Pharmacology, 2023
Introduction: Immune thrombocytopenia (ITP) is a complex autoimmune syndrome associated with low platelet count. Eltrombopag is an oral thrombopoietin receptor agonist that used in the treatment of chronic ITP.
Abdullah AL-Dhuraibi, Ahmad Khalaf Alkhawaldeh, Wadah Mohammed Al-Dhuraibi, Anna A. Peresypkina   +3 more
doaj   +1 more source

Impact of Eltrombopag Therapy in Different Lines of Treatment on Response in Patients with Immune Thrombocytopenia

İstanbul Medical Journal
Introduction: This study aimed to evaluate the results obtained with the preference of eltrombopag according to the line of treatment in patients diagnosed with ITP.
Abdülkadir Karışmaz, Vahit Can Çavdar, Istemi Serin, Rafet Eren   +3 more
doaj   +1 more source

Transcriptomic analysis of patients with immune thrombocytopenia treated with eltrombopag

Platelets, 2020
In the last years, the use of thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, has improved the management of immune thrombocytopenia (ITP).
Jesús María Hernández-Sánchez, José María Bastida, Diego Alonso-López, Rocío Benito, José Ramón González-Porras, Javier De Las Rivas, Jesús María Hernández Rivas, Ana Eugenia Rodríguez-Vicente   +7 more
doaj   +1 more source

Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study

, 2023
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet count and risk of bleeding. With the development of thrombopoietin receptor agonists, such as eltrombopag, the prognosis of ITP patients where first-line treatment has ...
Dijiong Wu
core   +1 more source

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag

Haematologica, 2021
Pretreatment blood counts, particularly an absolute reticulocyte count ≥25×109/L, correlate with response to immunosuppressive therapy in severe aplastic anemia.
Yoshitaka Zaimoku, Bhavisha A. Patel, Ruba Shalhoub, Emma M. Groarke, Xingmin Feng, Colin O. Wu, Neal S. Young   +6 more
doaj   +1 more source

Eltrombopag for the treatment of aplastic anemia: current perspectives [PDF]

, 2016
Su Han Lum, John D GraingerDepartment of Blood and Marrow Transplant, Royal Manchester Children’s Hospital, Manchester, UK Abstract: Aplastic anemia (AA) is a potential life-threatening hematopoietic stem cell (HSC) disorder resulting in cytopenia.
Lum SH, Grainger JD
core  

Treatment of immune thrombocytopenic purpura: focus on eltrombopag

, 2009
Lawrence RiceWeill Cornell Medical College, The Methodist Hospital, Houston, Texas, USAAbstract: Immune thrombocytopenic purpura (ITP) is a relatively common autoimmune disorder in which antibodies are produced to circulating platelets.
Lawrence Rice
core   +1 more source

Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

Balkan Medical Journal, 2023
Background: Eltrombopag has an off-label indication for haematopoietic cell transplantation in patients experiencing delayed thrombocyte recovery and/or thrombocytopaenia.
Ekin Kırcalı, Güldane Cengiz Seval, Cemaleddin Öztürk, Hülya Yılmaz, Derya Koyun, Sinem Civriz Bozdağ, Selami Koçak Toprak, Pervin Topçuoğlu, Önder Arslan, Muhit Özcan, Taner Demirer, Osman İlhan, Günhan Gürman, Meral Beksaç, Meltem Kurt Yüksel   +14 more
doaj   +1 more source